厄洛替尼二/三线治疗ⅢB/Ⅳ期非小细胞肺癌的临床研究

Clinical Study of Erlotinib as Second / Third Line Therapy in Treatment of Stage ⅢB/Ⅳ Non-small Cell Lung Cancer

摘要: 目的研究厄洛替尼二/三线治疗ⅢB/Ⅳ期非小细胞肺癌患者的疗效和不良反应。方法 2006年6月~2006年12月我院收治的30例晚期非小细胞肺癌患者，口服厄洛替尼150mg/d，直到病情进展或者因不良反应不能耐受为止。结果 30例患者0例完全缓解，7例部分缓解，16例稳定，7例进展，总缓解率7/30（23.3％），疾病控制率23/30（76.7％），中位生存时间（MST）11.5月，中位无疾病进展时间（PFS）8月。结论厄洛替尼二线/三线治疗非小细胞肺癌患者有确切疗效，不良反应较轻。

Abstract: Objective To evaluate the efficacy and adverse effects of erlotinib on the patients at stage ⅢB or Ⅳ of non-small cell lung cancer(NSCLC). Methods Thirty patients with advanced NSCLC received erlotinib orally at the dose of 150mg/d until disease progressed or intolerable adverse effects occurred from June to December 2006. Results None of the cases got complete remission, 7 cases got partial remission, 16 cases remained stable and 7 cases showed disease progression. The total remission rate was 7/30(23.3%). The disease-control rate was 23/30(76.7%), median overall survival was 11.5 months, while median progression-free survival was 8 months. Conclusion Erlotinib is an effective treatment for advanced NSCLC patients as second or third line therapy with few adverse effects.